Sinocelltech

Sinocelltech was founded in 2007, focusing on the research and development (R&D) and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins, and vaccines. It is an innovative biopharmaceutical R&D company dedicated to developing biologics with differentiated competitive advantages, specializing in the R&D and industrialization of monoclonal antibodies, recombinant proteins, vaccines, and other biopharmaceutical products.Since the establishment of Sinocelltech Engineering Co., Ltd., a subsidiary of the group, in 2002, the company has been committed to establishing a biopharmaceutical R&D and production technology platform with leading technical levels and cost advantages through life science and engineering technological innovation. It aims to address technical gaps and bottlenecks in new drug R&D and production, providing high-quality and economically affordable biopharmaceuticals for patients worldwide, thereby improving the accessibility of advanced biologics for patients in China and developing countries. Meanwhile, the company focuses on developing Best-in-Class or "Me-better" innovative biopharmaceutical products with differentiated competitive advantages in clinical settings, aiming to achieve the goal of having domestically developed and produced biologics enter the markets of developed countries in Europe and America, benefiting patients globally and establishing a leading international biopharmaceutical brand.The company's management team possesses extensive experience in biopharmaceutical R&D and production. The founder, Dr. Xie Liangzhi, pioneered the stoichiometric control-based fed-batch culture process for animal cells during his Ph.D. studies at MIT. In 1994, he increased antibody yields from 50 mg/L to a leading level of 2,400 mg/L, laying a crucial foundation for the scaled production of antibody drugs. After returning to China in 2002, he led several national "863 Program" projects and major special topics under the "New Drug Creation" initiative. He led the team in building a world-class biopharmaceutical R&D and industrialization technology platform, breaking through a series of key technologies and overcoming the complex production processes of recombinant Factor VIII, long-acting interferon-β, and 14-valent HPV vaccines. Dr. Wang Yang, Vice General Manager of the company, has over 20 years of experience in vaccine and antibody drug R&D and project management. He has led quality analysis and standard-setting work for cervical cancer vaccines and is an internationally renowned expert in biopharmaceutical quality control.The company conducted its Initial Public Offering (IPO) and was listed on the STAR Market of the Shanghai Stock Exchange on June 22, 2020.